MMP and TIMP temporal gene expression during osteocytogenesis by Prideaux, M. et al.
1 
 
MMP and TIMP temporal gene expression during osteocytogenesis 
Prideaux M1, Jones ER2, Riley GP2, Staines KA3, Pitsillides AA4, Farquharson C3 
1The University of Adelaide, North Terrace, Adelaide, SA, 5005, Australia 2 University of 
East Anglia, Norwich, NR4 7TJ 3 Roslin Institute and R(D)SVS, University of Edinburgh, 
Easter Bush, Midlothian, EH25 9RG 4Royal Veterinary College, Royal College Street, 
London, NW1 0TU 
Corresponding author 
Katherine Staines 
Roslin Institute and R(D)SVS 
University of Edinburgh 
Easter Bush 
Midlothian, EH25 9RG 
Email: katherine.staines@roslin.ed.ac.uk 
Tel: 0131 651 9176 
 
 
 
 
 
2 
 
1 Introduction 
Osteocytes within bone differentiate from osteoblast precursors.  They are the longest-lived 
and the most numerous cell type in bone (>90%), and are fundamental to its structure and 
function. Their characteristic dendritic morphology allows them to retain direct contact with 
bone-forming osteoblasts and to create multicellular networks permeating the entire bone 
matrix (Dallas et al., 2013). Osteocytes are now known to play key roles in calcium and 
phosphate homeostasis and are versatile orchestrators of bone remodelling in response to 
load-bearing (Pitsillides et al., 1995; Bonewald, 2002; Quarles, 2003; Franz-Odendaal et al., 
2006). Most models of osteocyte formation (osteocytogenesis) propose a predominantly 
passive role, during which an osteoblast destined for osteocytogenesis slows extracellular 
matrix (ECM) production and becomes surrounded by the osteoid synthesised by 
neighbouring osteoblasts (Nefussi et al., 1991; Palumbo et al., 2004; Franz-Odendaal et al., 
2006). Evidence, however, indicates that the initial ‘embedding’ stage involves a dynamic 
progression and that the essential genetic and dramatic morphological transformations taking 
place are part of an active process, closely regulated by the cells involved; not just simple 
entrapment of defunct osteoblasts within the matrix (Franz-Odendaal et al., 2006). 
Osteoblast-to-osteocyte transition occurs as the local ECM mineralises (Mikuni-Takagaki et 
al., 1995; Palumbo et al., 2004) and blockade of ECM mineralisation is accompanied by both 
lower expression of the earliest osteocyte marker E11, and by restricted formation of both 
osteocyte dendrites and sclerostin positive osteocytes (Irie et al., 2008; Prideaux et al., 2012). 
These and other studies confirm ECM mineralisation as a key player in pre-osteocyte 
maturation (Atkins et al., 2009a; Atkins et al., 2009b; Prideaux et al., 2012). 
Additional changes to the surrounding ECM have also been implicated in actively driving 
osteocytogenesis. As osteocytes are encased within the bone matrix there is a requirement for 
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collagen remodelling and mice rendered resistant to collagenase activity exhibit increased 
numbers of empty lacunae and apoptotic osteocytes (Zhou et al., 2000). The primary enzymes 
responsible for the remodelling of ECM proteins are matrix metalloproteinases (MMP) which 
are a family of metal-dependent endopeptidases.  MMPs are secreted in the form of inactive 
proenzymes and are activated in the tissue through the cleavage of pro-peptide (Krane, 1994).  
MMPs have long been recognised to be essential for embryonic and post-natal bone 
development, and are required for angiogenesis and vascular endothelial growth factor 
(VEGF) expression (Karelina et al., 1995; Raza and Cornelius, 2000; Eisenach et al., 2010).  
Elegant studies combining osteoblast lineage tracing with monitoring of the vascular 
endothelium have shown that osteoblast precursors at E12.5 within the perichondrium 
translocate to the nascent primary ossification centre giving rise to trabecular osteoblasts and 
cortical osteocytes by E16.5 (Maes et al., 2010). Throughout this translocation the osteoblast 
precursors are intimately associated with invading blood vessels; processes that require MMP 
activity for ECM remodelling. 
The importance of cleavage of collagen type 1 by MMP14 in particular has been 
demonstrated by the generation of mice lacking this enzyme (Holmbeck et al., 1999; 
Holmbeck et al., 2005). The osteocytes from these mice had a decreased number of cellular 
processes which were shorter and failed to achieve communication with neighbouring 
osteocytes. MMP14-null mice also had a ten-fold increase in apoptotic osteocytes which 
maybe via a decrease in the release of matrix bound TGF-β by the proteolytic activity of 
MMP14 (Karsdal et al., 2004). Similarly, MMPs 2, 13 and 10 have been localised to 
osteocytes (Zhou et al., 2000; Holmbeck et al., 2005; Inoue et al., 2006; Itoh and Seiki, 2006; 
Mosig et al., 2007; Tang et al., 2012; Blaber et al., 2013; Rocha et al., 2014). However, little 
is known about their precise role, and the expression patterns of other members of the 
extensive MMP family, during osteocytogenesis.  
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Therefore in this study we have used the murine MLO-A5 late osteoblastic cell line, which 
both synthesizes a mineralised matrix and expresses osteocyte markers, to describe the 
temporal changes in the transcriptional profile of members of the MMP family and their 
endogenous inhibitors – tissue inhibitors of metalloproteinases (TIMPs) during 
osteocytogenic transition (Kato et al., 2001b; Barragan-Adjemian et al., 2006; Prideaux et al., 
2012). Our studies identify several members of both families as potentially key regulators of 
ECM remodelling necessary for osteoblast – osteocyte transition. 
2 Results 
2.1 Matrix mineralisation in MLO-A5 cells 
MLO-A5 cells cultured in the presence of ascorbic acid and β-glycerophosphate achieved 
mineralisation of their associated matrix that was initially evident from day 3 of culture as 
shown by alizarin red staining. Quantification of eluted alizarin red revealed this 
mineralisation to be significantly increased from day 7 of culture onwards onwards (P<0.001; 
Fig. 1A & B). These data confirm our previous results with this cell line (Prideaux et al., 
2012) in which we found that these cells also progressively expressed osteocyte-selective 
markers such as E11, Dmp1, Sost and Cd44. This confirms the suitability of this model to 
report the gene expression patterns of Mmps and Timps during late-stage osteoblast 
differentiation and osteocytogenesis. 
2.2 Expression of Mmps and Timps during MLO-A5 cell differentiation  
We found that 14 Mmps and 3 Timps were expressed by MLO-A5 cells cultured in 
differentiating medium, whereas Mmps 1a, 1b, 7, 8, 12, 24, 25, 27 and Timp4 were not found 
to be expressed. We also observed weak and variable expression of Mmps 3, 9, 13 thus 
precluding them from temporal quantification. Of the expressed Mmps, several failed to show 
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any significant temporal changes in expression at any stage throughout the culture period 
(Mmp10, Mmp15, Mmp16, Mmp17 and Mmp21) whereas others showed clear and significant 
modulation. Our studies revealed that mRNA expression of both Mmp14 and Mmp19 were 
significantly increased at day 3 (‘a’; P<0.05) before returning to baseline levels at day 6 (Fig. 
2B & C). The mRNA expression of Mmp11 was also modestly increased, although not 
significant, at day 3 of culture, but in this case remained increased thereafter throughout the 
culture period (Fig. 2F). We also found that Mmp2, Mmp23 and Mmp28 had decreased 
expression concurrent with the onset of mineralisation at day 3 of culture (P<0.05) (Fig. 2A, 
D & E). Expression of Timp1, Timp2 and Timp3 mRNA each followed a similar pattern, with 
Timp2 analyses revealed significantly decreased levels of expression by day 6 compared to 
day 0 (P<0.05; Fig. 3A - C).  
2.3 The effects of blocking MLO-A5 cell differentiation on Mmp and Timp expression  
To examine whether these changes are linked to the process of osteocytic differentiation 
during matrix mineralisation, we also determined Mmp and Timp mRNA expression levels in 
conditions where mineralisation did not occur. Thus, in the absence of β-glycerophosphate 
there was a marked ablation of matrix mineralisation by MLO-A5 cells over the 10 day 
culture period (P<0.001) (Fig. 1A & B).  
In these conditions not favouring full osteocytic differentiation of MLO-A5 cells or 
mineralisation, the decreases in Mmp2, Mmp23 and Mmp28 expression previously noted in 
mineralising cultures by day 6 were not observed (Fig. 2A, D & E). Indeed, Mmp28 
expression levels were instead  increased at days 3 and 9 of culture compared to day 0 
(P<0.001, Fig. 2E), suggesting that the initiation and continued mineralisation of the MLO-
A5 cells is linked with the down-regulation of these MMPs and therefore closely associated 
with osteocyte differentiation. We also found that levels of Mmp14, Mmp19 and Mmp11 
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mRNA were also increased at day 3 compared to day 0 in the absence of β-glycerophosphate 
and, unlike MLO-A5 cells in differentiating medium,  these remained elevated throughout the 
culture period (P<0.05) (Fig. 2B, C & F). Interestingly, our studies also found that the 
expression of Timp3 mRNA was also affected by the omission of βGP from MLO-A5 
cultures, with increased expression observed on days 6 and 9 (P<0.001) of culture compared 
to cultures maintained in differentiating medium (Fig. 3C). Increased mRNA expression of 
Timp1 and Timp2 were also seen in the mineralisation-inhibited cultures after 9 days, 
compared to the control cultures (Fig. 3A & B). 
3 Discussion 
These gene expression patterns identify selective modulation of particular MMPs and their 
TIMP regulators during osteocyte differentiation and matrix mineralisation. In particular, 
they highlight that Mmp14 and Mmp19 show acute and transient up-regulation that coincides 
with MLO-A5 osteocytic differentiation, as shown by our previous profiling of osteocyte-
selective markers such as E11, Dmp1, Sost and Cd44 (Prideaux et al., 2012). We also show 
that Mmp2, Mmp23 and Mmp28, as well as the Timps1-3, in particular Timp3, show 
suppressed levels of expression upon osteocytogenic differentiation that are retained at low 
levels during matrix mineralisation by MLO-A5 cells. The reversal of these changing profiles 
of transcription in the absence of β-glycerophosphate links them closely with the 
mineralisation and osteocytogenesis of these cells.  
Remodelling of the ECM is pivotal for the development and maintenance of structural 
integrity of many tissues and key proteinases in this process are the MMPs; a family of 
secreted and cell surface enzymes known for their proteolytic activity (Sternlicht and Werb, 
2001; Itoh and Seiki, 2006).  They can be divided into two subgroups: membrane-tethered 
MMPs, which are expressed on the cell surface and soluble MMPs, which are secreted into 
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the extracellular matrix. MMPs are expressed in a variety of cell types and are essential for 
embryonic and post-natal bone development, as well as angiogenesis and VEGF expression 
(Karelina et al., 1995; Raza and Cornelius, 2000; Eisenach et al., 2010).  The actions of 
MMPs are moderated by their natural specific inhibitors – TIMPs which are required to work 
together in a balanced manner to remodel the ECM of a variety of tissues (Riley et al., 2002). 
To date the TIMP family consists of four members which have been localised to 
chondrocytes and osteoblasts and have a temporospatial expression during development of 
the mouse skeleton (Bord et al., 1999; Joronen et al., 2000). 
The importance of members of the MMP family of proteinases during osteocytogenesis has 
been demonstrated by the generation of Mmp14 (MT1-MMP) and Mmp2 knockout mice 
(Holmbeck et al., 1999; Zhou et al., 2000; Inoue et al., 2006; Mosig et al., 2007). These mice 
show defects in skeletal remodelling, reduced mineralisation and also show a profound effect 
on osteocyte formation characterised by a lack of cellular processes (Holmbeck et al., 2005; 
Inoue et al., 2006). These changes were particularly apparent in the MMP14 knockout mouse 
and identifies this member of the MMP family as playing a key regulatory role during 
osteoblast to osteocyte differentiation. MMP14 has also been implicated in mediating the 
osteocyte response to mechanical stimuli (Kulkarni et al., 2012). These mutant mice, along 
with MMP9 knockout mice, have also been shown to have defects in angiogenesis to varying 
degrees; in MMP14 knockout mice blood vessel growth is not observed where as it is simply 
reduced in MMP2 and MMP9 mutant mice (Vu et al., 1998; Zhou et al., 2000; Kato et al., 
2001a). Despite these associations between these MMPs and the skeleton, the expression 
patterns of MMPs during osteocytogenesis, however remains relatively unexplored and was 
the focus of this present study. 
Several MMPs were expressed in MLO-A5 cell cultures, with Mmp2 and Mmp14, as 
expected, amongst them (Fig. 4). Our data suggest that Mmp2 expression is decreased with 
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cell differentiation towards an osteocyte-like phenotype. In contrast, Mmp14 is increased, 
concurrent with initiation of mineralisation. However, its decreased expression at day 6 
suggests a role for Mmp14 in mineral deposition initiation and the formation of osteocytic 
processes, further enhancing the link between these two events. Mmp19 also followed a 
similar pattern of expression to that of Mmp14 in differentiating MLO-A5 cells. This is 
despite the fact that no role for MMP19 within the bone environment has so far been 
established and Mmp19 knockout mice do not display the gross abnormalities in bone 
phenotype exhibited by mice deficient in other MMPs (e.g. Mmp14) (Pendas et al., 2004). 
Two other MMPs, Mmp23 and Mmp28, were also decreased in expression during MLO-A5 
cell differentiation, with Mmp23 showing the greatest change in expression of all the MMPs 
analysed. Although the roles of both MMP23 and MMP28 in bone are currently unclear, 
Mmp23 mRNA has previously been detected in osteoblasts and chondrocytes (Clancy et al., 
2003) (Zaman et al., 2010) and microarray analysis revealed that its expression levels are 
significantly lower in osteocytes compared to osteoblasts (Paic et al., 2009). Mmp28 mRNA 
has previously been detected in rat bone (Bernal et al., 2005) but the specificity of expression 
within the bone environment in unknown. These results suggest that like Mmp23, Mmp28 is 
down-regulated during osteoblast to osteocyte differentiation. Further analysis of enzyme 
activity would be of importance to more fully delineate the precise role of these proteins in 
osteocytogenesis.  
The expression and activity of TIMPs, which act as endogenous inhibitors of MMP activity 
(Visse and Nagase, 2003) is unknown during osteocytogenesis. Timp1, Timp2 and Timp3 
mRNA expression has been observed in both osteoblasts and osteocytes (Hatori et al., 2004), 
which is in confirmed in the MLO-A5 cells of this study. Expression of these inhibitors was 
observed to decease with differentiation into an osteocyte-like phenotype. This is consistent 
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with the notion that a reduced blockade upon MMP activity is required during 
osteocytogenesis. No expression of Timp4 was detected in the MLO-A5 cell cultures. 
The inhibition of matrix mineralisation was also found to have a significant effect on Mmp 
mRNA expression by MLO-A5 cells. Indeed, the down- regulation of Mmp2, Mmp23 and 
Mmp28 expression which was observed during MLO-A5 cell differentiation under 
mineralising conditions, was lacking when mineralisation was inhibited, implying that these 
cells were not differentiating normally. Mmp14 expression in the mineralisation-inhibited 
cultures increased at day 3, similar to that in the control cultures, but then remained elevated 
even at the later timepoints. Mmp19 also showed a similar effect. These data indicate that 
mineralisation of the ECM which helps to drive osteocytogenesis is required for maintaining 
the correct MMP expression patterns associated with this process (Irie et al., 2008; Prideaux 
et al., 2012). The MMPs are known to be important in regulating cellular events such as 
adhesion, differentiation and morphology (Nagase et al., 2006; Page-McCaw, 2008). This 
disruption of MMP expression is likely to contribute to the detrimental effects on osteoblast-
to-osteocyte differentiation observed previously in both in vitro and in vivo studies (Irie et al., 
2008; Prideaux et al., 2012). 
Interestingly, forced expression of Mmp14 greatly reduced the mineralisation of rat osteoblast 
cultures in vivo, as did inhibition of MMP14 activity (Manduca et al., 2009). Mineralisation 
of MC3T3 osteoblast cultures was also significantly inhibited by the addition of a MMP14-
neutralising antibody before the initiation of mineralisation (Nakano et al., 2010). Addition of 
the MMP14-neutralising antibody after the initial onset of mineralisation had no effect on 
subsequent mineral deposition. Together with our data from MLO-A5 cells, these findings 
suggest that a transient peak in Mmp14 expression is required for mineralisation and 
osteocyte process formation to occur. Expression of Timp1, Timp2 and Timp3 mRNA was 
increased at day 9 in the mineralisation-inhibited MLO-A5 cultures compared to control 
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cultures. Timp1 and Timp2 have previously been shown to be down-regulated during late 
mineralisation (Filanti et al., 2000). This is supported by the present data which also show 
that the inhibition of mineralisation in MLO-A5 cells appears to maintain TIMP and reduce 
the down-regulation of their expression. 
4 Materials and methods 
4.1 Differentiation and mineralisation of MLO-A5 cell line 
MLO-A5 cells (a generous gift from Prof. Lynda Bonewald, University of Missouri-Kansas 
City, USA; passage number 21-22) were plated at a density of 3.5x104 cells/cm2 in 
maintenance media (α-MEM containing L-glutamine, ribonucleosides and 
deoxyribonucleosides, 0.5% gentamicin and 5% calf serum and 5% fetal bovine serum 
(FBS), (Invitrogen, Paisley, UK)) (Kato et al., 2001b). At confluency,  the media was 
replaced with differentiation media (α-MEM containing 0.5% gentamicin and 10% FBS) and 
mineral deposition was induced by supplementing the cultures with 100μg/ml ascorbic acid 
(AA) and 5mM β-glycerophosphate (βGP) (Prideaux et al., 2012). To inhibit matrix 
mineralisation, cells were cultured in (i) differentiation medium alone, (ii) differentiation 
medium lacking GP (100μg/ml AA alone), and (iii) differentiation medium lacking AA 
(5mM GP alone).   
4.2 Quantification of ECM mineralisation 
Cells were fixed with 4% paraformaldehyde (PFA) for 5 min at 4oC.  Cell layers were stained 
with aqueous 2% (w/v) Alizarin red solution (Sigma) at pH 4.2, for 5min at room temperature 
as previously described (Newton et al., 2012; Staines et al., 2012). The bound stain was 
subsequently solubilized in 10% cetylpyridinium chloride (Sigma) and the optical density of 
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the resultant solution determined at 570 nm by spectrophotometry (Thermo Multiskan 
Ascent). 
4.3 RNA extraction and reverse transcription 
Cultures were stopped at confluency (day 0) and thereafter, every 3 days and total RNA was 
extracted using Tri-Reagent (Ambion, Huntingdon UK) according to the manufacturer’s 
instructions.  Purified RNA was treated with DNase (Ambion, Paisley, UK).  RNA samples 
were reverse-transcribed using Superscipt II reverse transcriptase (Invitrogen) according to 
the manufacturer’s instructions.   
4.4 RT-qPCR of osteoblast/osteocyte markers 
RT-qPCR was carried out in a Stratagene Mx3000P cycler with each reaction containing 
50ng template DNA, 250nM forward and reverse primers (Primer Design, Southampton UK) 
(Table 1) and PrecisionPlus Mastermix (Primer Design). The Ct values for the samples were 
normalised to that of Gapdh and the relative expression was calculated using the ΔΔCt 
method (Livak and Schmittgen, 2001). The amplification efficiencies of all the primers were 
between 90-100%.  
4.5 Mmp and Timp mRNA profiling 
Mmp and Timp mRNA expression profiling was carried out by TaqMan qPCR analysis. 
Briefly, 50ng cDNA derived from 3 individual cultures at each timepoint was amplified in 
duplicate using ProbeFast 2x qPCR MasterMix (Kapa Biosystems), 200nmol/l forward and 
reverse primer and 100nm/l probe (Table 1) (Wilkinson et al., 2012). Reactions were cycled 
on an Applied Biosystems 7500 Real Time PCR system under the following conditions: 
50°C, 2min; 95°C, 1min; 40 cycles of 95°C, 15sec and 60°C, 1min. The results were 
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normalized to 18S and the relative expression was calculated using the ΔΔCt method (Livak 
and Schmittgen, 2001).  
5 Statistical analysis  
Data are expressed as the mean ± SEM. Statistical analysis was performed by two way 
analysis of variance (ANOVA). P<0.05 was considered to be significant and noted ‘*’; P 
values of <0.01 and <0.001 were noted as ‘**’ and ‘***’ respectively. 
6 Conclusions 
In conclusion, this study has profiled the temporal expression patterns of members of the 
MMP and TIMP families of proteins during osteoblast differentiation. This approach has 
identified several members of both families as potentially key regulators of ECM remodelling 
necessary for osteoblast – osteocyte transition.  
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Figure Legends 
Figure 1. Alizarin red staining (A) and relative quantification of absorbance of eluted alizarin 
red staining (B) in mineralising MLO-A5 cells cultured with 100μg/ml ascorbic acid ± 5mM 
β-glycerophosphate. Data are represented as mean ± S.E.M. of 3 individual cell cultures. ‘a’ 
= P<0.001*** in comparison to ascorbic acid only cultures. 
Figure 2. Effects of inhibition of mineralisation on Mmp expression in MLO-A5 cell 
cultures. RT-qPCR analysis of (A) Mmp2 (B) Mmp14 (C) Mmp19 (D) Mmp23 (E) Mmp28 
(F) Mmp11 mRNA expression in mineralising MLO-A5 cells ± βGP over a 9-day culture 
period. Data are represented as mean ± S.E.M. of 5 individual cell cultures. P<0.05*, 
P<0.01**, P<0.001***. ‘a’ = P<0.05* in comparison to day 0 of culture.   
 Figure 3. Effects of mineralisation inhibition on Timp expression in MLO-A5 cell cultures. 
RT-qPCR analysis of (A) Timp1 (B) Timp2 (C) Timp3 mRNA expression in mineralising 
MLO-A5 cells ± βGP over a 9-day culture period. Data are represented as mean ± S.E.M. of 
5 individual cell cultures. P<0.001***. ‘a’ = P<0.05* in comparison to day 0 of culture.    
Figure 4. Hypothetical schematic representation of the temporal expression of Mmp and 
Timp mRNA during differentiation and matrix mineralisation of MLO-A5 cells. 
